Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies by Delveinsight | Zurex Pharma, Dr. Reddy’s Laboratories, Botanix Pharma, Menarini Group Pharma and Others 1
Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies by Delveinsight | Zurex Pharma, Dr. Reddy's Laboratories, Botanix Pharma, Menarini Group Pharma and Others
Surgical Site Infection Market

DelveInsight’s “Surgical Site Infection Market” report provides a thorough comprehension of the Surgical Site Infection, historical and forecasted epidemiology, and the Surgical Site Infection market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Surgical Site Infection market report also proffers an analysis of the current Surgical Site Infection treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 


Some of the vital takeaways of the Surgical Site Infection Market Research Report 

  • A slew of companies such as Zurex Pharma, Dr. Reddy’s Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma, and others are developing Surgical Site Infection therapies to influence treatment outlook. 
  • In Nov 2020, PolyPid Ltd. announced that D-PLEX100 received Breakthrough Therapy Designation from the US Food and Drug Administration to prevent Surgical Site Infections in patients undergoing elective colorectal surgery.
  • The prophylactic therapy segment is XF-73 under development by Destiny Pharma with its antimicrobial “XF” drug platform. XF-73 was awarded QIDP status in October 2015.
  • Presently the emerging therapies such as XF-73, D-PLEX100, DFA-02, BTX 1801, ZuraGard, and others are focused on treating or preventing Surgical Site Infection in either cardio or abdominal surgeries in the prophylactic segment, while Delafloxacin is used for the Surgical Site Infection treatment. 
  • Under the Surgical Site Infection treatment market, Delafloxacin by Menarini Group is the only upcoming therapy for a patient with incisional, superficial or deep, surgical site infection after cardiothoracic/related leg or abdominal surgery.
  • Delafloxacin, under the name of Baxdela (fluoroquinolone antibacterial), received FDA approval for the Acute Bacterial Skin and Skin Structure Infections treatment, announced by Melinta Therapeutics in June 2017. 
  • Menarini Group and Melinta Therapeutics entered into a co-development and commercial agreement in 68 Countries for Delafloxacin in 2017. 
  • The future development of new modalities in Surgical Site Infection treatment and prophylaxis appears promising during the forecast period of 2021–2030. Of the emerging therapies, XF-73, D-PLEX100, BTX 1801, Delafloxacin, DFA-02, Zuragard, and others are expected to change the Surgical Site Infection market scenario in the upcoming years. 


Request for free Sample Report:


Surgical Site Infections (SSIs) are the most common nosocomial infection and frequently cause morbidity and mortality among patients of hospitals. 

As per DelveInsight’s research, the total Surgical Site Infection Incident cases in the 7MM were 1,323,491 cases in 2018. Moreover, it is observed that males and females are equally affected.


Surgical Site Infection Emerging Therapies Along with Key Players

  • XF-73: Destiny Pharma
  • D-PLEX100: PolyPid
  • Delafloxacin: Menarini Group Pharma
  • BTX 1801: Botanix Pharma
  • DFA-02: Dr Reddy’s Laboratories Ltd.
  • Zuragard: Zurex Pharma 
  • And several others.


Get a sample copy of this report:


Scope of the Surgical Site Infection Market Insight Report 

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • Surgical Site Infection Markets Segmentation: By Geographies and By Surgical Site Infection Therapies (Historical and Forecasted, Current and Upcoming) 
  • Dominant Market Companies investigating its candidates for Surgical Site Infection: Zurex Pharma, Dr. Reddy’s Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma, and several others. 
  • Analysis: Comparative and conjoint analysis of emerging therapies. 
  • Case Studies
  • KOL’s Views
  • Analyst’s View


Request for free Sample Report:


Table of Contents 

1 Surgical Site Infection Key Insights
2 Surgical Site Infection Report Introduction
3 Surgical Site Infection Prophylactic Market Overview at a Glance
4 Surgical Site Infection Treatment Market Overview at a Glance
5 Surgical Site Infection Executive Summary
6 Surgical Site Infection Disease Background and Overview 
7 Surgical Site Infection Epidemiology and Patient Population
7.1 The United States
7.2 EU5 Countries
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 Spain
7.2.5 The United Kingdom
7.3 Japan
8 Surgical Site Infection Treatment and Management 
9 Surgical Site Infection Prevention
10 Organizations contributing towards Surgical Site Infection
11 Surgical Site Infection Patient Journey
12 Surgical Site Infection Case Report
13 Surgical Site Infection Emerging Therapies
13.1 XF-73: Destiny Pharma
13.2  D-PLEX100: PolyPid
13.3 Delafloxacin: Menarini Group Pharma
13.4 BTX 1801: Botanix Pharma
13.5 DFA-02: Dr. Reddy’s Laboratories Ltd.
13.6 Zuragard: Zurex Pharma
14 7MM Surgical Site Infection Market Analysis
14.1 The United States Surgical Site Infection Market Size
14.2 EU-5 Surgical Site Infection Market Size
14.2.1 Germany Market Size
14.2.2 France Market Size
14.2.3 Italy Market Size
14.2.4 Spain Market Size
14.2.5 The United Kingdom Market Size
14.3 Japan Surgical Site Infection Market Size
15 Surgical Site Infection Market Drivers
16 Surgical Site Infection Market Barriers
17 SWOT Analysis of Surgical Site Infection
18 Surgical Site Infection Unmet Needs
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight

Request for Detailed TOC:


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States